Epocrates has finally launched a native iPad version of it's landmark drug information app, up until now a conspicuous and much-discussed omission. The release is part of a larger strategy by CEO Andy Hurd to turn around the struggling company, which posts its second annual loss this year on revenue estimates of about $110 million.
In an October 30 quarterly investor's call, Hurd mentioned data...
